Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod Before Surgery in Treating Patients With Recurrent or Metastatic Colorectal Cancer That Can Be Removed By Surgery

Inclusion Criteria

• Recurrent and/or metastatic resectable colorectal cancer, including disease within the abdomen and pelvis with no evidence of extra-abdominal metastases; intra-abdominal disease includes: isolated hepatic metastasis/metastases (see next inclusion criteria point), isolated peritoneal metastasis, or a combination of hepatic and extrahepatic metastasis
• Patients with isolated hepatic metastasis must satisfy a Clinical Risk Score of 3 or higher
• Eligible patients are expected to have a complete resection based on preoperative imaging; any patient not found to be able to have complete resection will not be eligible for this study
• No chemotherapy, radiotherapy, major surgery, or biologic therapy within 3 weeks of protocol treatment
• An Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
• Platelet >= 75,000/uL
• Hemoglobin >= 9.0 g/dL
• Hematocrit >= 27.0%
• Absolute Neutrophil Count (ANC) >= 1500/uL
• Creatinine < institutional upper limit of normal (ULN) OR creatinine clearance >= 50 mL/min/1.73 m^2 for patients with creatinine levels greater than ULN
• Total bilirubin =< 1.5 X institutional upper limit of normal (ULN)
• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT)(serum glutamate pyruvate transaminase [SGPT]) =< 2.5 X institutional upper limit of normal (ULN)
• Serum amylase and lipase within normal limits
• Patient must be able to understand and be willing to sign a written informed consent document

Exclusion Criteria

• Patients currently treated with systemic immunosuppressive agents, including steroids, are ineligible until 3 weeks after removal from immunosuppressive treatment
• Patients with active autoimmune disease or history of transplantation
• Patients who are pregnant or nursing; women of childbearing potential (WOCBP) will have to undergo a urine pregnancy test as part of screening
• Patients with comorbid medical conditions that render them unfit for surgery
• Metastatic or recurrent disease that is deemed partially resectable or unresectable based on preoperative imaging
• Metastatic disease outside the confines of the abdomen and pelvis (such as lung, bone, brain)
• Cardiac risk factors including: * Patients experiencing cardiac event(s) (acute coronary syndrome, myocardial infarction, or ischemia) within 3 months of signing consent * Patients with a New York Heart Association classification of III or IV
• History of upper gastrointestinal ulceration, upper gastrointestinal bleeding, or upper gastrointestinal perforation within the past 3 years; patients with ulceration, bleeding or perforation in the lower bowel are not excluded
• Prior allergic reaction or hypersensitivity to sulfonamides, celecoxib, or nonsteroidal anti-inflammatory drugs (NSAIDs)
• Patients are ineligible if they plan on regular use of NSAIDs at any dose more than 2 times per week (on average) or aspirin at more than 325 mg at least three times per week, on average; low-dose aspirin not exceeding 100 mg/day is permitted; patients who agree to stop regular NSAIDs or higher dose aspirin are eligible and no wash out period is required